A woman has taken to the internet to share the biggest difference she experienced when switching between GLP-1 drugs Wegovy ...

Explore how GLP-1 drugs like Ozempic, Wegovy, and Mounjaro are impacting obesity rates in America, while also highlighting ...

Eli Lilly raised its full-year profit and revenue forecast on Thursday as strong appetite for its widely popular weight-loss ...

Lilly tops Q3 estimates as Mounjaro and Zepbound fuel a 54% revenue surge, prompting the drugmaker to raise its full-year ...

Novo Nordisk's late bid to hijack Pfizer's takeover of U.S. obesity biotech Metsera marks an aggressive shift from the Danish ...

Eli Lilly reported higher profit and raised its outlook on surging demand for its weight-loss drugs, sending its shares ...

Amy Schumer unveiled her slimmer figure after losing about 40lbs, crediting the weight-loss drug Mounjaro for her ...

Eli Lilly’s blockbuster drug Mounjaro has quickly become the market leader in the segment, thanks to its strong clinical performance and early entry advantage.

The government is pushing to designate Wegovy and Mounjaro, among other new obesity treatments, as “medicines of concern for ...

U.S. sales of Lilly’s weight-loss treatment Zepbound nearly tripled, to $3.57 billion, in the third quarter. Meanwhile, ...

Worth noting, CVS Caremark—the biggest PBM in the U.S.— announced in May that it would make Novo Nordisk’s rival drug Wegovy ...

Shares of the world's largest healthcare company by market value were up nearly 2% in morning trading even as investors remain wary of drug price negotiations with the Trump administration.